Context Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CNTX and other ETFs, options, and stocks.About CNTX
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.
CEOMartin A. Lehr
CEOMartin A. Lehr
Employees12
Employees12
HeadquartersPhiladelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded2015
Founded2015
Employees12
Employees12
CNTX Key Statistics
Market cap132.31M
Market cap132.31M
Price-Earnings ratio-5.43
Price-Earnings ratio-5.43
Dividend yield—
Dividend yield—
Average volume2.44M
Average volume2.44M
High today$1.53
High today$1.53
Low today$1.42
Low today$1.42
Open price$1.49
Open price$1.49
Volume1.12M
Volume1.12M
52 Week high$2.00
52 Week high$2.00
52 Week low$0.49
52 Week low$0.49
Stock Snapshot
As of today, Context Therapeutics(CNTX) shares are valued at $1.46. The company's market cap stands at 132.31M, with a P/E ratio of -5.43.
During the trading session on 2026-01-16, Context Therapeutics(CNTX) shares reached a daily high of $1.53 and a low of $1.42. At a current price of $1.46, the stock is +2.8% higher than the low and still -4.9% under the high.
Trading activity shows a volume of 1.12M, compared to an average daily volume of 2.44M.
The stock's 52-week range extends from a low of $0.49 to a high of $2.00.
The stock's 52-week range extends from a low of $0.49 to a high of $2.00.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CNTX. This list is generated using Robinhood data, and it’s not a recommendation.